within Pharmacolibrary.Drugs.ATC.H;

model H01CB01
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 0.00013833333333333333,
    adminDuration  = 600,
    adminMass      = 250 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.013699999999999999,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 0.0065,
    k12             = 10.2,
    k21             = 10.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>H01CB01</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Somatostatin is a cyclic peptide hormone that inhibits the secretion of several other hormones, such as growth hormone, insulin, and glucagon. It is used therapeutically to control bleeding from esophageal varices and in the management of certain endocrine and gastrointestinal disorders. Due to its very short half-life, somatostatin is generally used only in hospital settings for acute indications. Synthetic analogues (e.g., octreotide) are commonly used instead for chronic therapy.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters are mainly derived from studies in healthy adult volunteers following intravenous infusion.</p><h4>References</h4><ol><li><p>Harris, AG (1994). Somatostatin and somatostatin analogues: pharmacokinetics and pharmacodynamic effects. <i>Gut</i> 35(3 Suppl) S1–S4. DOI:<a href=\"https://doi.org/10.1136/gut.35.3_suppl.s1\">10.1136/gut.35.3_suppl.s1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7911441/\">https://pubmed.ncbi.nlm.nih.gov/7911441</a></p></li><li><p>Qin, S, et al., &amp; Yu, F (2023). Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using . <i>Molecular pharmaceutics</i> 20(11) 5543–5553. DOI:<a href=\"https://doi.org/10.1021/acs.molpharmaceut.3c00427\">10.1021/acs.molpharmaceut.3c00427</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/37788300/\">https://pubmed.ncbi.nlm.nih.gov/37788300</a></p></li><li><p>Gottesman, I, et al., &amp; Gerich, J (1986). Efficacy, pharmacokinetics and tolerability of a somatostatin analogue (L-363,586) in insulin-dependent diabetes mellitus. <i>Life sciences</i> 38(24) 2211–2219. DOI:<a href=\"https://doi.org/10.1016/0024-3205(86)90573-4\">10.1016/0024-3205(86)90573-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2872569/\">https://pubmed.ncbi.nlm.nih.gov/2872569</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end H01CB01;
